Skip to main content
Equibles

RADX · Radiopharm Theranostics Ltd

Track RADX — free

Use RADX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RADX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.04 +0.07 (+7.48%)
Rebalance outlook locked
Market Cap
$14.05M
Shares
14.59M
Volume · Oct 20 3262 Avg daily vol (3M) 91.02K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.96 Open$1.01 Day$0.96–1.14 52W close$0.96–10.63 Avg vol 30d60K Short int34K · 0.2% float · 1.0d Short vol53% DataDec 2024–Oct 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
-23.8%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+49.9%
Year over year · more shares
Price change (1Y)
-86.5%
Trailing year
Short interest
0.2%
Latest settlement · 1.0 days to cover
View all 116 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 18.4 · elevated Equity put/call 0.55
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −75%
below
Price vs 50-day avg −49%
below
RSI (14) 24
oversold
MACD trend Positive
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −40%
trailing
6-month return −79%
trailing
YTD return −82%
this year
Relative strength −86%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $4 — 200d above 50d
Institutional flow Distributing
-14% holders QoQ
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.24% of float · ▼ -18.7% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
6 holders — mid 1-yr range
Squeeze score 33
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 171%
annualized · 1-yr
Max drawdown −91%
past year
ATR 21.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−75% Bearish
Price vs 50-day avg
−49% Bearish
RSI (14)
24 Neutral
MACD trend
Positive Bullish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $2 › 200d $4 — 200d above 50d
Institutional flow Distributing
-14% holders QoQ
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.24% of float · ▼ -18.7% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
6 holders — mid 1-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 0% Range high $11
vs 200-day avg -75% vs 50-day avg -49%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
RADX
Radiopharm Theranostics Ltd
this stock
$14.05M -81.6% — — 0.2%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.07B +10.7% +46.2% 29.9 1.8%
MRNA
Moderna, Inc.
 $90.58B +669.4% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.51B +1.3% +20.8% 19.4 2.1%
CSLLY
Csl Ltd
 $64.50B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
6
% held
350.4%
Net QoQ
-184.0K sh
Top holder
Stonepine Capital Managem…
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
34.3K
Days to cover
1.0d
Change
-7.9K sh
View
Short Volume
Short vol %
53%
As of
Oct 19, 2026
Short Total
View
Fails to Deliver
FTD shares
3
Value
$5
As of
Sep 28, 2026
View
Off-Exchange
Off-exchange %
42.6%
Week of
Sep 14, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
6-K
Filed
Oct 20, 2026
This year
39

Radiopharm Theranostics Limited reported listed-option cancellations across four director notices and issued 140,028,000 unquoted employee incentive options.

View
Earnings & Events
Webcasts
Last webcast
Oct 16, 2026
View

Performance

5D 20D 120D MTD YTD
RADX -13.2% -40.2% -78.7% -40.6% -81.6%
SPY -1.5% -0.9% +7.7% +0.5% +12.4%
vs SPY -11.8% -39.3% -86.4% -41.1% -94.0%
Key facts CIK 1949257 CUSIP 75041J101 Visit website Investor relations